E-ISSN 2367-699X | ISSN 2367-7414
 
2020, Vol: 6, Issue: 3
6/3Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles TOP 20 Reviewers in 2015-2017 TOP 20 Reviewers in 2018 TOP 20 Reviewers in 2019 Rewarding Publication
Required files to be uploaded

Copyright Transfer Form

Original Research 


DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian.

Cited by (2)

Abstract
Colorectal cancer (CRC) is one of the most deadly cancers worldwide. Despite the introduction of targeted molecular therapies in the last 10 years, overall survival has not increased substantially. CRC progression is accompanied by numerous genetic and epigenetic alterations and dysregulation of several signaling pathways, among which activation of Wnt and inactivation of TGF-β signaling. The molecular heterogeneity of CRC, however, hinders the molecular subtyping of CRC and thus the identification of common biomarkers for this pathology. The only three well established biomarkers for advanced-colorectal-cancer drug treatment are negative biomarkers. These are mutations in the genes KRAS, NRAS and BRAF which determine resistance to therapy with anti-EGFR antibodies. YKL-40 is a chitin-binding glycoprotein that has been shown to play a role in extracellular tissue remodeling, angiogenesis, cell migration and inflammation. Increased serum levels of this protein have been detected in patients with CRC but the role of YKL-40 in this neoplastic disease has not been studied extensively and the precise function of YKL-40 in CRC progression is not known. In the present study we determined the KRAS mutation status and measured the mRNA levels of YKL-40 of 24 patients with sporadic CRC. In addition, we assessed the association between these two parameters by statistical analysis. We are the first to show that in CRC YKL-40 mRNA levels are dependent on the presence of KRAS mutations, being prominently elevated in the wild type background. Our results indicate the potential role of YKL-40 as a target molecule for CRC therapy.

Key words: colorectal cancer (CRC), YKL-40 gene expression, KRAS mutations, target therapy


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Yana Feodorova
Articles by Dessislava Tashkova
Articles by Kiril Simitchiev
Articles by Anton Todorov
Articles by Gancho Kostov
Articles by Rossen Dimov
Articles by Victoria Sarafian
on Google
on Google Scholar


REFERENCES
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Reprint of: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2015; 51(9): 1201-2. [DOI via Crossref]   
2. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15(10): 1065-75. [DOI via Crossref]   
3. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32(21): 2240-7. [DOI via Crossref]    [Pubmed]   
4. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 2012; 27(9): 1423-31. [DOI via Crossref]    [Pubmed]   
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61(5): 759-67. [DOI via Crossref]   
6. Akkad J, Bochum S, Martens UM. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbecks Arch Surg 2015; 400(2): 129-43. [DOI via Crossref]    [Pubmed]   
7. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407): 330-7. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
8. Dienstmann R, Salazar R, Tabernero J. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. Am Soc Clin Oncol Educ Book 2014; 91-9. [DOI via Crossref]    [Pubmed]   
9. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19(5): 619-25. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
10. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013; 10(5): e1001453. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
11. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013; 231(1): 63-76. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
12. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014; 134(3): 552-62. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
13. Dienstmann R, Guinney J, Delorenzi M, De Reynies A, Roepman P, Sadanandam A, et al. O-0025 colorectal cancer subtyping consortium (crcsc) identifies consensus of molecular subtypes. Ann Oncol 2014; 25, ii115. [DOI via Crossref]   
14. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998; 251(1-2): 504-9. [DOI via Crossref]    [Pubmed]   
15. Chen CC, Pekow J, Llado V, Kanneganti M, Lau CW, Mizoguchi A, et al. Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia. Am J Pathol 2011; 179(3): 1494-503. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
16. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006; 53(2): 172-209. [Pubmed]   
17. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, Yan W, Bentley B, Shao R. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011; 286(17): 15332-43. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
18. Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol 2014; 31(8): 85. [DOI via Crossref]    [Pubmed]   
19. Johansen JS, Christensen IJ, Jørgensen LN, Olsen J, Rahr HB, Nielsen KT, et al. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2015; 24(3): 621-6. [DOI via Crossref]    [Pubmed]   
20. Kazakova MH, Staneva DN, Koev IG, Staikov DG, Mateva N, Timonov PT, Miloshev GA, Sarafian VS. Protein and mRNA levels of YKL-40 in high-grade glioma. Folia Biol (Praha) 2014; 60(6): 261-7.
21. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) 2013; 1(3): 166-83. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
22. Kazakova M, Batalov A, Deneva T, Mateva N, Kolarov Z, Sarafian V. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int 2013; 33(2): 341-6. [DOI via Crossref]    [Pubmed]   
23. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002; 62(15): 4364-8. [Pubmed]   
24. Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, et al. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. Oncol Rep 2014; 32(1): 159-66. [DOI via Crossref]   
25. Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008; 25(8): 801-9. [DOI via Crossref]    [Pubmed]   
26. Stawerski P, Wągrowska-Danilewicz M, Stasikowska-Kanicka O, Danilewicz M. Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers. Pathol Res Pract 2011; 207(9): 573-6. [DOI via Crossref]    [Pubmed]   
27. Fan JT, Li MJ, Shen P, Xu H, Li DH, Yan HQ. Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol 2014; 35(3): 304-8. [Pubmed]   
28. Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer 2011; 105(8): 1203-9. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
29. Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol 2014; 32(5): 663-9. [DOI via Crossref]    [Pubmed]   
30. Senetta R, Duregon E, Sonetto C, Spadi R, Mistrangelo M, Racca P, et al. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study. PLoS One 2015; 10(4): e0123759. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   

This Article Cited By the following articles

Novel insights into transcriptional dysregulation in colorectal cancer
Neoplasma 2018; 65(03): 415-424.

1
 
Role of chitinase-like proteins in cancer
Biological Chemistry 2016; 0(0): .

2
 
How to Cite this Article
Pubmed Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian. DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS. Int J Surg Med. 2015; 1(2): 43-47. doi:10.5455/ijsm.20150723012230

Web Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian. DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS. http://www.ejos.org/?mno=195942 [Access: July 05, 2020]. doi:10.5455/ijsm.20150723012230

AMA (American Medical Association) Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian. DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS. Int J Surg Med. 2015; 1(2): 43-47. doi:10.5455/ijsm.20150723012230


Vancouver/ICMJE Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian. DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS. Int J Surg Med. (2015), [cited July 05, 2020]; 1(2): 43-47. doi:10.5455/ijsm.20150723012230


Harvard Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian (2015) DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS. Int J Surg Med, 1 (2), 43-47. doi:10.5455/ijsm.20150723012230


Turabian Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian. 2015. DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS. International Journal of Surgery and Medicine, 1 (2), 43-47. doi:10.5455/ijsm.20150723012230


Chicago Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian. "DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS." International Journal of Surgery and Medicine 1 (2015), 43-47. doi:10.5455/ijsm.20150723012230


MLA (The Modern Language Association) Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian. "DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS." International Journal of Surgery and Medicine 1.2 (2015), 43-47. Print. doi:10.5455/ijsm.20150723012230


APA (American Psychological Association) Style

Yana Feodorova, Dessislava Tashkova, Kiril Simitchiev, Anton Todorov, Gancho Kostov, Rossen Dimov, Victoria Sarafian (2015) DEPENDENCE OF YKL-40 mRNA TISSUE LEVELS ON KRAS MUTATION STATUS IN COLORECTAL CANCER - PRELIMINARY RESULTS. International Journal of Surgery and Medicine, 1 (2), 43-47. doi:10.5455/ijsm.20150723012230


Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights) Privacy Policy Publishing Ethics Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information
Copyright © 2020 International Journal of Surgery and Medicine All Rights Reserved. Subject to change without notice from or liability to International Journal of Surgery and Medicine.
For best results, please use Internet Explorer or Google Chrome

Contact Information


 

Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.